DK3621694T3 - Lrrc33-inhibitorer og anvendelse heraf - Google Patents
Lrrc33-inhibitorer og anvendelse heraf Download PDFInfo
- Publication number
- DK3621694T3 DK3621694T3 DK18727561.5T DK18727561T DK3621694T3 DK 3621694 T3 DK3621694 T3 DK 3621694T3 DK 18727561 T DK18727561 T DK 18727561T DK 3621694 T3 DK3621694 T3 DK 3621694T3
- Authority
- DK
- Denmark
- Prior art keywords
- lrrc33
- inhibitors
- lrrc33 inhibitors
- Prior art date
Links
- 101001004913 Homo sapiens Transforming growth factor beta activator LRRC33 Proteins 0.000 title 1
- 102100025954 Transforming growth factor beta activator LRRC33 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503785P | 2017-05-09 | 2017-05-09 | |
| US201762558048P | 2017-09-13 | 2017-09-13 | |
| US201862663030P | 2018-04-26 | 2018-04-26 | |
| US201862666182P | 2018-05-03 | 2018-05-03 | |
| PCT/US2018/031759 WO2018208888A1 (en) | 2017-05-09 | 2018-05-09 | Lrrc33 inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3621694T3 true DK3621694T3 (da) | 2023-09-11 |
Family
ID=62245483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18727561.5T DK3621694T3 (da) | 2017-05-09 | 2018-05-09 | Lrrc33-inhibitorer og anvendelse heraf |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200181251A1 (da) |
| EP (2) | EP4286013A3 (da) |
| JP (1) | JP2020519579A (da) |
| AU (1) | AU2018266784A1 (da) |
| CA (1) | CA3099260A1 (da) |
| DK (1) | DK3621694T3 (da) |
| ES (1) | ES2958587T3 (da) |
| FI (1) | FI3621694T3 (da) |
| HR (1) | HRP20230742T1 (da) |
| HU (1) | HUE063120T2 (da) |
| LT (1) | LT3621694T (da) |
| PL (1) | PL3621694T3 (da) |
| PT (1) | PT3621694T (da) |
| SI (1) | SI3621694T1 (da) |
| WO (1) | WO2018208888A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| TW202035445A (zh) | 2018-10-10 | 2020-10-01 | 美商帝洛斯療法股份有限公司 | 抗lap抗體變異體及其用途 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| CN114807038B (zh) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
| WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
| WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013341353B2 (en) | 2012-11-06 | 2017-03-16 | Children's Medical Center Corporation | Compositions and methods for modulating cell signaling |
| AU2014262843B2 (en) | 2013-05-06 | 2017-06-22 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| KR20180122397A (ko) | 2016-03-11 | 2018-11-12 | 스칼러 락, 인크. | TGFβ1-결합 이뮤노글로불린 및 그의 용도 |
| EP3532494A4 (en) | 2016-10-26 | 2020-06-03 | The Children's Medical Center Corporation | METHOD AND COMPOSITIONS FOR MODULATING TRANSFORMATION GROWTH FACTOR BETA-REGULATED FUNCTIONS |
-
2018
- 2018-05-09 DK DK18727561.5T patent/DK3621694T3/da active
- 2018-05-09 EP EP23183427.6A patent/EP4286013A3/en active Pending
- 2018-05-09 ES ES18727561T patent/ES2958587T3/es active Active
- 2018-05-09 PT PT187275615T patent/PT3621694T/pt unknown
- 2018-05-09 EP EP18727561.5A patent/EP3621694B1/en active Active
- 2018-05-09 CA CA3099260A patent/CA3099260A1/en active Pending
- 2018-05-09 HU HUE18727561A patent/HUE063120T2/hu unknown
- 2018-05-09 FI FIEP18727561.5T patent/FI3621694T3/fi active
- 2018-05-09 PL PL18727561.5T patent/PL3621694T3/pl unknown
- 2018-05-09 AU AU2018266784A patent/AU2018266784A1/en active Pending
- 2018-05-09 US US16/611,029 patent/US20200181251A1/en not_active Abandoned
- 2018-05-09 HR HRP20230742TT patent/HRP20230742T1/hr unknown
- 2018-05-09 WO PCT/US2018/031759 patent/WO2018208888A1/en unknown
- 2018-05-09 LT LTEPPCT/US2018/031759T patent/LT3621694T/lt unknown
- 2018-05-09 SI SI201830969T patent/SI3621694T1/sl unknown
- 2018-05-09 JP JP2019560657A patent/JP2020519579A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018208888A1 (en) | 2018-11-15 |
| PL3621694T3 (pl) | 2024-02-05 |
| PT3621694T (pt) | 2023-10-09 |
| AU2018266784A1 (en) | 2019-12-05 |
| EP4286013A2 (en) | 2023-12-06 |
| JP2020519579A (ja) | 2020-07-02 |
| US20200181251A1 (en) | 2020-06-11 |
| FI3621694T3 (fi) | 2023-08-28 |
| HUE063120T2 (hu) | 2023-12-28 |
| SI3621694T1 (sl) | 2023-10-30 |
| EP4286013A3 (en) | 2024-02-28 |
| LT3621694T (lt) | 2023-11-27 |
| EP3621694B1 (en) | 2023-07-05 |
| ES2958587T3 (es) | 2024-02-12 |
| CA3099260A1 (en) | 2018-11-15 |
| EP3621694A1 (en) | 2020-03-18 |
| HRP20230742T1 (hr) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3380101T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3521289T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf | |
| DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
| DK3672976T3 (da) | Bcl-2-hæmmere | |
| DK3536698T3 (da) | Lanosterol-prodrugforbindelse og anvendelse deraf | |
| DK3668512T3 (da) | Pyruvatkinasemodulatorer og anvendelse deraf | |
| DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
| DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| DK3430129T3 (da) | Kolonidannende medium og anvendelse deraf | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3426243T3 (da) | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf | |
| DK3142659T3 (da) | Hiv-1 proteasehæmmere og anvendelser deraf | |
| DK3692009T3 (da) | Biocementationsfremgangsmåde og system | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| MA49905A (fr) | Polyesteramines et polyesterquats | |
| DK3426934T3 (da) | Monteringsholdeanordninger og fremgangsmåder |